You're contacting media contact of this press release

Title: Citius Pharmaceuticals Nears Key FDA Decisions and Launch Plans for 2024

Carrollton, Texas, United States, 11th Jul 2024 - In the rapidly evolving world of biotechnology, certain companies stand out not only for their innovative product pipelines but also for their strategic milestones and operational execution. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a late-stage biopharmaceutical company, is one such entity that investors and traders should keep a close eye on. With a clear focus on critical care products, Citius has demonstrated significant progress and is poised for potentially transformative catalysts in the latter half of 2024.Strategic Advances in Citius's PipelineMino-Lok®, a Game Changer for Catheter-Related InfectionsOne of the most significant developments at Citius is their antibiotic lock solution, Mino-Lok®, which has shown promise in Phase 3 studies for treating catheter-related bloodstream infections (CRBSIs). Mino-Lok® could revolutionize the standard of care by providing a first-of-its-kind solution for salvaging infected central venous catheters, potentially avoiding the need for catheter removal, which can be risky and costly.LYMPHIR™, Pioneering Cutaneous T-cell Lymphoma TreatmentAnother cornerstone of Citius's late-stage assets is LYMPHIR™, an IL-2-based immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). With the FDA currently reviewing the Biologics License Application (BLA) for LYMPHIR™, an approval decision is eagerly anticipated on August 13, 2024. Approval could grant Citius 12 years of exclusivity, positioning the company as a leader in this niche market.Operational Excellence and Financial HealthCitius has not only been advancing its clinical programs but also strengthening its financial position. A recent $15 million registered direct offering has extended the compan...

This press release is issued by King Newswire